<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478280</url>
  </required_header>
  <id_info>
    <org_study_id>PsoPET2</org_study_id>
    <nct_id>NCT03478280</nct_id>
  </id_info>
  <brief_title>Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis</brief_title>
  <official_title>Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab
      monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with
      moderate-to-severe plaque-type psoriasis who are candidates for systemic therapy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomised, double-blind, placebo-controlled, trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The aortic wall inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <description>The average of maximum TBR values (MeanTBRmax) of the entire aorta at baseline and at week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The splenic inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <description>The spleen-to-liver ratio (SLR) based on splenic and liver mean standardised uptake values (SUVmean)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The aortic wall subsegment inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <description>The average of maximum TBR values (MeanTBRmax) of the ascending, aortic arch, descending, suprarenal, and infrarenal aorta at baseline and at week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The skin inflammation at baseline and at week 16 in brodalumab treated psoriasis subjects compared to placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Severity of psoriasis measured by PASI score at baseline and at week 16</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Brodalumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brodalumab</intervention_name>
    <description>Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period</description>
    <arm_group_label>Brodalumab</arm_group_label>
    <other_name>Kyntheum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained from the subject prior to performing any
             protocol-related procedures.

          2. Age 40 and above.

          3. Diagnosis of chronic plaque psoriasis confirmed by a dermatologist

          4. PASI ≥ 10

        Exclusion Criteria:

          1. Non-Danish speaking

          2. Known or suspected allergy or reaction to any component of the IMP formulation.

          3. History of inflammatory bowel disease, arthritis (not including psoriatic arthritis),
             systemic lupus erythematosus, and active inflammatory skin diseases.

          4. A history of malignancies within the past five years (excluding localized non-melanoma
             skin cancer).

          5. Topical corticosteroid treatment (class III or stronger) and/or ultraviolet type B
             phototherapy within 2 weeks prior to randomization

          6. Treatment with psoralen plus ultraviolet type A photochemotherapy, methotrexate,
             cyclosporine, acitretin, or fumaric acid esters within 4 weeks prior to randomization.

          7. Treatment with adalimumab, etanercept, infliximab, cosentyx, or ixekizumab within 12
             weeks, ustekinumab within 24 weeks, or other immunosuppressive or anti-inflammatory
             agents within 5 half-lives of the active substance prior to the FDG-PET/CT,
             respectively.

          8. Scheduled surgery during the trial period (expect minor minimally invasive
             procedures).

          9. Systemic infection or fever within 7 days prior to FDG-PET/CT.

         10. Severe obesity (&gt; 150 kg due to a PET/CT scanner limitation).

         11. Presence of uncontrolled diabetes mellitus (HbA1c &gt; 75 mmol/mol and/or blood sugar &gt;
             11.1 mmol/l and/or clinical judgment).

         12. History of coagulation defects (clinical judgment).

         13. Active or latent tuberculosis requiring treatment.

         14. Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb),
             hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology at
             screening. Subjects with positive HBsAb may be randomised provided they are hepatitis
             B vaccinated and have negative HBsAg and HBcAb.

         15. History of any known primary immunodeficiency disorder including a positive human
             immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral
             medications as determined by medical history and/or subject's verbal report.

         16. No history of varicella zoster infection and negative varicella antibody test (until
             varicella vaccination is completed).

         17. History of chronic alcohol or drug abuse within 12 months prior to screening, or any
             condition associated with poor compliance as judged by the investigator.

         18. History of intravenous drug use.

         19. History of attempted suicide or is at significant risk of suicide.

         20. Major surgery within the past 3 months.

         21. Pregnancy or lactation (Women of childbearing potential must use a highly effective*
             form of birth control (confirmed by the investigator) throughout the trial and until
             12 weeks after discontinuation of treatment with brodalumab.

         22. Claustrophobia.

         23. Reduced renal function (serum creatinine &gt; 200 μmol/L or cr-EDTA clearance &lt; 30
             ml/min)

         24. Any disorder, including but not limited to, cardiovascular, lung, gastrointestinal,
             hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,
             haematological, immunological, psychiatric, or major physical impairment that is not
             stable, in the opinion of the investigator, and could:

               -  Affect the safety of the subject throughout the trial.

               -  Influence the findings of the trial or their interpretations.

               -  Impede the subject's ability to complete the entire duration of trial.

                    -  A highly effective method of birth control is defined as one which results
                       in a low failure rate (less than 1% per year) such as bilateral tubal
                       occlusion, intrauterine device (IUD), intrauterine hormone-releasing system
                       (IUS), combined (estrogen and progestogen containing) hormonal contraception
                       associated with inhibition of ovulation (oral, intravaginal, transdermal),
                       progestogen-only hormonal contraception associated with inhibition of
                       ovulation (oral, injectable, implantable), sexual abstinence (when this is
                       in line with the preferred and usual life style of the subject),
                       vasectomised partner (given that the subject is monogamous). The subjects
                       must have used the contraceptive method continuously for at least 1 month
                       prior to the pregnancy test. A female is defined as not being of child
                       bearing potential if she is postmenopausal (at least 12 months with no
                       menses without an alternative medical cause prior to screening), or
                       surgically sterile (hysterectomy, bilateral salpingectomy or bilateral
                       oophorectomy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Bregnhøj, MD, PhD</last_name>
    <phone>+45 2183 5720</phone>
    <email>annebreg@rm.dk</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Anne Bregnhøj</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

